HLA system affects the age-at-onset in chronic myeloid leukemia

American Journal of Hematology

Volumn 73, Issue 4, 2003, Pages 256-262

  Oguz, Fatma Savran ^a   Kalayoglu, Sevgi ^a   Diler, A Sarper ^a   Tozkir, Hilmi ^a   Sargin, Deniz ^a   Carin, Mahmut ^a   Dorak, M Tevfik ^b,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chronic myeloid leukemia; Genetic susceptibility; HLA DR; Major histocompatibility complex

Indexed keywords

BCR ABL PROTEIN; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B14 ANTIGEN; HLA B35 ANTIGEN; HLA B37 ANTIGEN; HLA DR ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; B3A2 GENE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FUSION GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HLA TYPING; HOMOZYGOSITY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; ONSET AGE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; STEM CELL TRANSPLANTATION; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; TURKEY;

EID: 0041808711     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10365     Document Type: Article

References (42)

1. Dorak MT, Chalmers EA, Gaffney D, et al. Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 1994;12:211-222.
2. Dorak MT, Machulla HK, Hentschel M, Mills KI, Langner J, Burnett AK. Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia. Int J Cancer 1996;65:134-139.
3. Dorak MT, Lawson T, Machulla HKG, Darke C, Mills KI, Burnett AK. Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood 1999;94:694-700.
4. Dorak MT, Oguz FS, Yalman N, et al. A male-specific increase in the HLA-DRB4 (DR53) frequency in high-risk and relapsed childhood ALL. Leuk Res 2002;26:651-656.
5. Yasukawa M, Ohminami H, Kojima K, Inokuchi K, Nishimura Y, Fujita S. Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol 2000;63:99-101.
6. Taylor GM, Dearden S, Ravetto P, et al. Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet 2002;11:1585-1597.
7. Barrett A, Jiang YZ. Immune responses to chronic myeloid leukaemia. Bone Marrow Transplant 1992;9:305-311.
8. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol 1997;54:61-67.
9. Toren A, Mandel M, Amariglio N, et al. Lack of bcr rearrangement in juvenile chronic myeloid leukemia. Med Pediatr Oncol 1991;19:493-495.
10. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997;10:203-222.
11. Maclntyre AR, Christmas SE, Clark RE. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol 1996;24:1307-1311.
12. Pawelec G, Max H, Halder T, et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996;88:2118-2124.
13. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-3592
14. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996;88:3522-3527.
15. Greco G, Fruci D, Accapezzato D, et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:693-699.
16. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995;85:2680-2684.
17. Yasukawa M, Ohminami H, Kaneko S, et al. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998;92:3355-3361.
18. Yasukawa M, Ohminami H, Kojima K, et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Blood 2001;98:1498-1505.
19. Clark RE, Dodi IA, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001;98:2887-2893.
20. The MHC Sequencing Consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999;401:921-923.
21. Allcock RJ, Atrazhev AM, Beck S, et al. The MHC haplotype project: a resource for HLA-linked association studies. Tissue Antigens 2002;59:520-521.
22. Lilly F, Boyse EA, Old LJ. Genetic basis of susceptibility to viral leukaemogenesis. Lancet 1964;ii:1207-1209.
23. Lilly F. The inheritance of susceptibility to the Gross leukemia virus in mice. Genetics 1966;53:529-539.
24. Boyse EA, Old LJ, Stockert E. The relation of linkage group IX to leukemogenesis in the mouse. In: Emmelot P, Bentvelzen P, editors. RNA viruses and host genome in oncogenesis. Amsterdam: North Holland Publishers Co.; 1972. p 171-185.
25. Miyazawa M, Nishio J, Chesebro B. Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med 1988;168:1587-1605.
26. Vasmel WL, Zijlstra M, Radaszkiewicz T, Leupers CJ, de Goede RE, Melief CJ. Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J Virol 1988;62:3156-3166.
27. Dorak MT, Sproul AM, Gibson BE, Burnett AK, Worwood M. The C282Y mutation of HFE is another male-specific risk factor for childhood ALL [letter]. Blood 1999;94:3957-3958.
28. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-235.
29. Weir BS. Inferences about linkage disequilibrium. Biometrics 1979;35:235-254.
30. Yeh FC, Yang RC, Boyle TBJ, Ye ZH, Mao JX. 1997. POPGENE, the user-friendly shareware for population genetic analysis. Edmonton, Alberta, Canada: Molecular Biology and Biotechnology Centre, University of Alberta, Canada (http://www.ualberta.ca/~fyeh/index.htm).
31. Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-2515.
32. Hirano N, Takahashi T, Takahashi T, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-1176.
33. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. Blood 1999;93:3863-3865.
34. Richiardi PM, Tosi R, Martinelli G, et al. The HLA class I-CML association revisited taking into account the two forms of gene fusion in the Philadelphia chromosome. A multicenter study. Leukemia 1994;18:2134-2137.
35. Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma 2002;43:467-477.
36. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia 2000;14:859-862.
37. Zijlstra M, Melief CJ. Virology, genetics and immunology of murine lymphomagenesis [Review]. Biochim Biophys Acta 1986;865:197-231.
38. Pollack MS, Levine LS, O'Neill GJ, et al. HLA linkage and B14, DR1, BfS haplotype association with the genes for late onset and cryptic 21-hydroxylase deficiency. Am J Hum Genet 1981;33:540-550.
39. Dondi E, Cuccia M, Keller E, Martinetti M, Larizza D, Albert ED. Molecular analysis of CYP21 gene mutations carried on HLA-B14 positive haplotypes. Eur J Immunogenet 1994;21:341-350.
40. Gordon GB, Helzlsouer KJ, Comstock GW. Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 1991;51:1366-1369.
41. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc 1995;274:1926-1930.
42. Wang DY, Allen DS, De Stavola BL, et al. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br J Cancer 2000;82:1577-1584.